Todd Anderman - IVERIC Bio Gen VP
| ISEEDelisted Stock | USD 39.95 0.00 0.00% |
Insider
Todd Anderman is Gen VP of IVERIC Bio
| Phone | 609 474 6755 |
| Web | https://ivericbio.com |
Todd Anderman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Todd Anderman against IVERIC Bio stock is an integral part of due diligence when investing in IVERIC Bio. Todd Anderman insider activity provides valuable insight into whether IVERIC Bio is net buyers or sellers over its current business cycle. Note, IVERIC Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell IVERIC Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Todd Anderman over a month ago Insider Trading |
IVERIC Bio Management Efficiency
The company has return on total asset (ROA) of (0.2964) % which means that it has lost $0.2964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5502) %, meaning that it created substantial loss on money invested by shareholders. IVERIC Bio's management efficiency ratios could be used to measure how well IVERIC Bio manages its routine affairs as well as how well it operates its assets and liabilities.IVERIC Bio currently holds 97.77 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. IVERIC Bio has a current ratio of 11.74, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about IVERIC Bio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Rik Derynck | Pliant Therapeutics | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Ryan Martins | 89bio Inc | 45 | |
| Michael MBA | Arcellx | N/A | |
| Rakhi Kumar | Roivant Sciences | 44 | |
| MBA MD | Immunovant | 43 | |
| Johannes Hull | Pliant Therapeutics | 49 | |
| Kelly Graff | Roivant Sciences | N/A | |
| Richard Pulik | Roivant Sciences | 44 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| MD MBA | Pliant Therapeutics | 47 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Marianne Mancini | Viking Therapeutics | 59 | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
Management Performance
| Return On Equity | -0.55 | |||
| Return On Asset | -0.3 |
IVERIC Bio Leadership Team
Elected by the shareholders, the IVERIC Bio's board of directors comprises two types of representatives: IVERIC Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IVERIC. The board's role is to monitor IVERIC Bio's management team and ensure that shareholders' interests are well served. IVERIC Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IVERIC Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pravin MD, President | ||
| Todd Anderman, Gen VP | ||
| Keith MBA, VP COO | ||
| Christopher Simms, VP Officer | ||
| XiaoPing Dai, Chief Officer | ||
| Kathy Galante, Sr Communications | ||
| David MBA, CFO VP | ||
| Glenn MBA, CEO Director | ||
| Samir Patel, CoFounder Consultant | ||
| Anthony Gibney, Exec Officer |
IVERIC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IVERIC Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | |||
| Return On Asset | -0.3 | |||
| Current Valuation | 4.98 B | |||
| Shares Outstanding | 137.98 M | |||
| Shares Owned By Insiders | 0.65 % | |||
| Shares Owned By Institutions | 99.35 % | |||
| Number Of Shares Shorted | 16.64 M | |||
| Price To Earning | 4.17 X | |||
| Price To Book | 3.81 X | |||
| Gross Profit | (117.01 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in IVERIC Stock
If you are still planning to invest in IVERIC Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the IVERIC Bio's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |